A Phase 3 interventional study of Sublingual film containing dexmedetomidine (BXCL501) and Placebo Film in Agitation, Schizophrenia and Schizo Affective Disorder, sponsored by BioXcel Therapeutics Inc. Completed at 15 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by BioXcel Therapeutics Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,465 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.
Among the 1,465 studies in Schizophrenia with a site in United States, this one is the 149th largest by enrollment of the 1,319 interventional ones that give a count, is one of 44 that started in 2020, is one of 196 in phase 3, and was the 1,164th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →148 of the 1,465 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 18–55
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Stanford University · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,465 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 228 · Phase 2 271 · Phase 3 218 · Phase 4 193
First in 1983; this study’s year is marked. 44 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 380 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 66 across the 1,319 interventional studies, 163 across the 128 observational. Of the 1,234 that completed or were terminated, 603 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
517 of 1,465 have an industry lead sponsor. The 10 most frequent:
BioXcel Therapeutics Inc is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 9 (75%) have results posted.
BioXcel Therapeutics Inc has 6 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
52 of the studies in Schizophrenia with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT03817502Phase 3Gedeon Richter Plc.Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia | 2026-12-15 |
| NCT06191965Phase 3Mclean HospitalMitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction | 2027-01-31 |
| NCT07184619Phase 3Newron Pharmaceuticals SPAEvenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia | 2027-03-31 |
| NCT07363577Phase 3LB Pharmaceuticals Inc.Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia | 2027-06 |
Add all 52 to your calendar (.ics) → With an account.
Among the 1,465 studies in Schizophrenia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in schizophrenia. The BXCL501-301 study is designed to characterize the efficacy, safety and tolerability of BXCL501 (sublingual film formulation of DEX, HCl) in agitation associated with schizophrenia, schizoaffective disorder or schizophreniform disorder.
The study will enroll approximately 375 subjects randomized 1:1:1 to dose regimens of 180µg, 120µg BXCL501, or placebo. Male and female adults with acute agitation associated with schizophrenia, schizoaffective disorder, or schizophreniform disorder will be enrolled. Eligible subjects may be identified in outpatient clinics, mental health, psychiatric or medical emergency services including medical/psychiatric observation units, or as newly admitted to a hospital setting for acute agitation or already in hospital for chronic underlying conditions. Subjects will be domiciled in a clinical research setting or hospitalized to remain under medical supervision while undergoing screening procedures to assess eligibility. Efficacy and safety assessments will be conducted periodically before and after dosing.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
This study's enrollment of 380 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Browse Schizophrenia studies →BioXcel Therapeutics Inc is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 9 (75%) have results posted.
Compared within Schizophrenia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Psychomotor Agitation. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A subject will be eligible for inclusion in the study if he or she meets the following criteria:
Exclusion Criteria:
A subject will be excluded from the study if he or she meets the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sublingual film containing 120 Micrograms dexmedetomidine
Drug: Sublingual film containing dexmedetomidine (BXCL501)
Sublingual film containing 180 Micrograms dexmedetomidine
Drug: Sublingual film containing dexmedetomidine (BXCL501)
Sublingual placebo film
Drug: Placebo Film
Sublingual film containing dexmedetomidine (BXCL501)
Also known as: Dexmedetomidine
Placebo Film for BXCL501
Also known as: Placebo
Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score
The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).
Time frame: Baseline and 2 hours
Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score Over Time
Effect on agitation onset was measured by change from baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) total score. The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).
Time frame: Baseline and 10, 20, 30, 45, 60, 90 minutes post-dose
| Milestone | 120 Micrograms | 180 Micrograms | Placebo |
|---|---|---|---|
| Started | 129 | 125 | 126 |
| Completed | 126 | 123 | 123 |
| Not completed | 3 | 2 | 3 |
| Withdrew: Lost to follow-up | 1 | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 |
| Withdrew: Adverse event | 2 | 0 | 0 |
The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).
| score on a scale | 120 Micrograms | 180 Micrograms | Placebo |
|---|---|---|---|
| Baseline | 17.5 ± 2.46 | 17.6 ± 2.69 | 17.6 ± 2.26 |
| 2 Hours | -8.4 ± 4.83 | -10.4 ± 4.34 | -4.7 ± 4.69 |
Effect on agitation onset was measured by change from baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) total score. The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).
| score on a scale | 120 Micrograms | 180 Micrograms | Placebo |
|---|---|---|---|
| Baseline | 17.5 ± 2.46 | 17.6 ± 2.69 | 17.6 ± 2.26 |
| 10 minutes | -1.3 ± 2.50 | -2.0 ± 3.19 | -1.3 ± 2.17 |
| 20 minutes | -2.8 ± 4.03 | -3.9 ± 4.54 | -2.5 ± 3.20 |
| 30 minutes | -4.4 ± 4.90 | -5.7 ± 5.27 | -3.1 ± 3.56 |
| 45 minutes | -5.7 ± 5.18 | -7.6 ± 5.32 | -3.6 ± 3.78 |
| 60 minutes | -6.9 ± 5.06 | -8.8 ± 4.96 | -4.1 ± 4.16 |
| 90 minutes | -8.0 ± 5.00 | -9.8 ± 4.60 | -4.6 ± 4.38 |
Collected over 30 days. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 120 Micrograms | 0/129 (0%) | 0/129 (0%) | 51/129 (39.5%) |
| 180 Micrograms | 0/126 (0%) | 0/126 (0%) | 47/126 (37.3%) |
| Placebo | 0/126 (0%) | 0/126 (0%) | 19/126 (15.1%) |
| Event | 120 Micrograms | 180 Micrograms | Placebo |
|---|---|---|---|
| SomnolenceNervous system disorders | 28/129 | 29/126 | 10/126 |
| Dry mouthGastrointestinal disorders | 10/129 | 5/126 | 2/126 |
| DizzinessNervous system disorders | 3/129 | 8/126 | 1/126 |
| HypotensionVascular disorders | 8/129 | 5/126 | 0/126 |
| Hypoesthesia oralNervous system disorders | 5/129 | 7/126 | 0/126 |
| Orthostatic hypotensionVascular disorders | 2/129 | 7/126 | 0/126 |
| HeadacheNervous system disorders | 6/129 | 4/126 | 6/126 |
| Paresthesia oralNervous system disorders | 5/129 | 3/126 | 1/126 |
Safety population (all participants who received study drug). One participant enrolled and randomized to the 120 μg group was enrolled a second time at a different site and randomized to the 180 μg group. The data from the first enrollment and treatment (120 μg) were included in the efficacy analyses. The data from both enrollments (120 μg and 180 μg) were included in the safety analyses and counted separately for each treatment group.
| Age, Continuous(years) | 120 Micrograms | 180 Micrograms | Placebo | Total |
|---|---|---|---|---|
| Mean | 45.7 ± 11.3 | 46.0 ± 11.9 | 45.1 ± 11.1 | 45.6 ± 11.4 |
| Sex: Female, Male(Participants) | 120 Micrograms | 180 Micrograms | Placebo | Total |
|---|---|---|---|---|
| Female | 52 | 43 | 44 | 139 |
| Male | 77 | 82 | 82 | 241 |
| Ethnicity (NIH/OMB)(Participants) | 120 Micrograms | 180 Micrograms | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 17 | 13 | 7 | 37 |
| Not Hispanic or Latino | 112 | 112 | 119 | 343 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | 120 Micrograms | 180 Micrograms | Placebo | Total |
|---|---|---|---|---|
| Black or African American | 92 | 102 | 102 | 296 |
| White | 33 | 21 | 21 | 75 |
| Other | 4 | 2 | 3 | 9 |
| Hispanic or Latino | 17 | 13 | 7 | 37 |
| Positive and Negative Syndrome Scale-Excited Component(units on a scale) | 120 Micrograms | 180 Micrograms | Placebo | Total |
|---|---|---|---|---|
| Mean | 17.5 ± 2.5 | 17.6 ± 2.7 | 17.6 ± 2.3 | 17.6 ± 2.5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2020 to primary completion in May 2020, 3 months.
Results were first posted in Jun 2023, 3 years 1 month after primary completion.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 3 months is below that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
BioXcel Therapeutics Inc